CDCécile Delattre

Cécile Delattre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Cécile Delattre has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Carine Bellera

    Clinical Research & Clinical Epidemiology Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France; INSERM CIC 14.01 Bordeaux, Clinical epidemiology unit- INSERM U1219 Research Centre, Epicene Team (Epidemiology of Cancer and Environmental Exposure), France

    1 shared publication
  • Damien Heitz

    Oncology and Hematology Unit, Strasbourg University Hospital, Hautepierre Hospital, F-67200 Strasbourg, France

    1 shared publication
  • Elena Paillaud

    Univ Paris Est Creteil, INSERM, IMRB, Creteil, France

    1 shared publication
  • Etienne Brain

    Department of Medical Oncology, Institut Curie, Saint-Cloud, France

    1 shared publication
  • Florence Canoui-Poitrine

    Service de Santé Publique, GHU AP-HP Hôpitaux Universitaires Henri-Mondor, Créteil; UMR U955 - UPEC/Inserm U955, Faculté de Médecine de Créteil, Créteil, France; Département Masters, Faculté de Santé - UPEC, Créteil, France

    1 shared publication
  • Gilles Albrand

    Department of Geriatrics, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, F-69310 Pierre-Bénite, France

    1 shared publication

Latest Publications

  • Open Access

    Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts

    by Nadia Oubaya, Pierre Soubeyran, Nicoleta Reinald, Marianne Fonck, Mylène Allain, Sonia Zebachi, Damien Heitz, Marie Laurent, Cécile Delattre, Philippe Caillet, et al.

    Background: The prognostic assessment of older cancer patients is complicated by their heterogeneity. We aimed to assess the prognostic value of routine inflammatory biomarkers. Methods: A pooled analysis of prospective multicenter cohorts of cancer patients aged ≥70 was performed. We measured CRP and albumin, and calculated Glasgow Prognostic Score (GPS) and CRP/albumin ratio. The GPS has three levels (0 = CRP ≤ 10 mg/L, albumin ≥ 35 g/L, i.e., normal values; 1 = one abnormal value; 2 = two abnormal values). One-year mortality was assessed using Cox models. Discriminative power was assessed using Harrell’s C index (C) and net reclassification improvement (NRI). Results: Overall, 1800 patients were analyzed (mean age: 79 ± 6; males: 62%; metastases: 38%). The GPS and CRP/albumin ratio were independently associated with mortality in patients not at risk of frailty (hazard ratio [95% confidence interval] = 4.48 [2.03–9.89] for GPS1, 11.64 [4.54–29.81] for GPS2, and 7.15 [3.22–15.90] for CRP/albumin ratio > 0.215) and in patients at risk of frailty (2.45 [1.79–3.34] for GPS1, 3.97 [2.93–5.37] for GPS2, and 2.81 [2.17–3.65] for CRP/albumin ratio > 0.215). The discriminative power of the baseline clinical model (C = 0.82 [0.80–0.83]) was increased by adding GPS (C = 0.84 [0.82–0.85]; NRI events (NRI+) = 10% [2–16]) and CRP/albumin ratio (C = 0.83 [0.82–0.85]; NRI+ = 14% [2–17]). Conclusions: Routine inflammatory biomarkers add prognostic value to clinical factors in older cancer patients.